Investigation into ACADIA Pharmaceuticals
Pomerantz LLP, a notable law firm, is taking steps to investigate possible claims concerning shareholders of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). This investigation focuses on whether the company, along with its officers and directors, may have participated in securities fraud or engaged in other unlawful business practices.
Recent Developments
Recently, ACADIA Pharmaceuticals announced results from its Phase 3 COMPASS trial. This trial was evaluating the effects of intranasal carbetocin in patients with hyperphagia associated with Prader-Willi syndrome (PWS). The outcomes disclosed that the medication did not present a significant improvement compared to a placebo on the primary endpoint. Due to these results, the firm's Head of Research and Development noted that there will be no further investigation into intranasal carbetocin.
Impact on Stock Price
The announcement about the trial outcomes triggered a notable decline in ACADIA's stock price. On the day of the announcement, shares fell by $2.34, marking a decrease of nearly 10%. Investors reacted swiftly as the market took heed of the disappointing results from the trial.
About Pomerantz LLP
Pomerantz LLP is recognized as a leading firm specializing in corporate, securities, and antitrust class actions. The firm, founded by renowned attorney Abraham L. Pomerantz, has a long history of advocating for the rights of investors and holding companies accountable for their actions. With multiple offices globally, including cities such as New York, Chicago, and Los Angeles, Pomerantz remains a significant player in the field of securities law.
Focus on Investor Rights
Investor rights are paramount to Pomerantz's mission. The firm's legacy of fighting against securities fraud has led to substantial recoveries for many class members over the years. Their commitment to ensuring justice for those harmed by corporate misconduct continues to shape the landscape of securities litigation.
How to Get Involved
If you are an investor affected by ACADIA Pharmaceuticals' recent disclosures, it is advisable to reach out to the firm for assistance. They are keen to connect with individuals who may have relevant information or claims regarding potential misconduct.
Contact Information
For further details, interested parties should contact Danielle Peyton at Pomerantz LLP. The firm encourages affected investors to make their voices heard and seek justice for any losses incurred due to alleged corporate actions.
Frequently Asked Questions
What is the focus of the investigation into ACADIA Pharmaceuticals?
The investigation by Pomerantz aims to determine whether ACADIA and its executives engaged in securities fraud or other unlawful activities.
What sparked the recent stock price decline for ACADIA?
The drop in stock price was triggered by disappointing results from the Phase 3 COMPASS trial regarding intranasal carbetocin.
Who can I contact for more information about this case?
Investors can contact Danielle Peyton at Pomerantz LLP for further information and assistance.
What kind of law does Pomerantz LLP specialize in?
Pomerantz LLP specializes in corporate, securities, and antitrust class actions, fighting for investor rights.
How has Pomerantz LLP contributed to investor rights?
Over the years, Pomerantz has recovered significant damages for investors, demonstrating their commitment to combating corporate misconduct.
